Close

Baird Reiterates an 'Outperform' on Incyte (INCY) following Confirmatory Phase 3 Details for Ruxolitinib Jun 6, 2011 04:27PM
Notable Analyst Rating Changes 1/15: AMD, NRG, K, OMX, PRIM Upgraded; TOL, INCY, AYR, CTCM, PAYX Downgraded Jan 15, 2010 10:55AM
Baird Maintains an Outperform Rating on Incyte (INCY); Comments on New Data Dec 8, 2009 07:24AM
RW Baird Makes Positive Comments on Incyte (INCY) Following Novartis Deal Nov 25, 2009 09:26AM
Incyte (INCY) Strikes Major Drug Development Deal with Noavartis Nov 25, 2009 09:20AM


Apr 16, 2008 08:49AM Color on Baird Coverage of Incyte (INCY)
Apr 16, 2008 07:32AM Baird Initiates Coverage on Incyte (INCY) with an Outperform